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Abstract
Background: Chronic kidney disease (CKD) patients present elevated advanced glycation end products (AGEs) blood levels.
AGEs promote inflammation through binding to their receptor (RAGE), located on the membrane of mesangial cells,
endothelial cells and macrophages. Several genetic polymorphisms influence RAGE transcription, expression and activity,
including the substitution of a thymine with an adenine (T/A) in the position -374 of the gene promoter of RAGE. Our study
investigates the role of -374 T/A RAGE polymorphism in CKD progression in subjects affected by nephrocardiovascular
disease.
Methods: 174 patients (119 males (68.4%) mean age 67.260.88 years; 55 females (31.6%): mean age 65.461.50 years)
affected by mild to moderate nephrocardiovascular CKD were studied. Each subject was prospectively followed for 84
months, every 6–9 months. The primary endpoint of the study was a rise of serum creatinine concentrations above 50% of
basal values or end stage renal disease.
Results: Carriers of the A/A and T/A genotype presented higher plasma levels of interleukin 6 (A/A 29.5615.83; T/A
30.067.89, vs T/T 12.365.04 p = 0.01 for both) and Macrophages chemoattractant protein 1 (A/A 347.1639.87; T/A
411.8648.41, vs T/T 293.5636.20, p = 0.04 for both) than T/T subjects. Carriers of the A allele presented a faster CKD
progression than wild type patients (Log-Rank test: Chi square = 6.84, p = 0,03). Cox regression showed that -374 T/A RAGE
polymorphism (p= 0.037), albuminuria (p = 0.01) and LDL cholesterol (p = 0.038) were directly associated with CKD
progression. HDL cholesterol (p = 0.022) and BMI (p = 0.04) were inversely related to it. No relationship was found between
circulating RAGE and renal function decline.
Conclusions: -374 T/A RAGE polymorphism could be associated with CKD progression and inflammation. Further studies
should confirm this finding and address whether inhibiting RAGE downstream signalling would be beneficial for CKD
progression.
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Introduction
Oxidative stress (OS) is one of the main causes associated with
chronic kidney disease progression (CKD). Beyond aging, diabetes
and hypertension, several mechanisms contribute the production
of reactive oxygen species (H2O2, OH
2, O.) in CKD, including
vitamin C deficiency due to malnutrition [1], impairment of
antioxidant mechanisms [2,3]), inflammation [4] and increased
levels of advanced glycation end products (AGEs), as a
consequence of their impaired renal clearance [5]. The interaction
between AGEs and their receptor (RAGE) located on monocytes
[6], T- lymphocytes [7] and endothelial cells [8,9], enhances NF-
kB-mediated [10] cellular production of cytokines, including
interleukin-1 (IL-1), interleukin 6 (IL-6), Tumor Necrosis Factor
a (TNF-a) and cell adhesion molecules. These events induce OS
and reduce endothelial nitric oxide synthetase activity, thus
resulting in endothelial dysfunction, a hallmark of cardiovascular
complications, especially in diabetic patients [11].
RAGE is present either as a transmembrane receptor or as
soluble protein (sRAGE). The latter acts as a decoy for circulating
AGEs thus limiting the interaction between AGEs and membrane
RAGE [12]. The gene is located on chromosome 6 (6p21.32
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region). The transcription of the RAGE towards the soluble form
rather than the membrane anchored form depends on two
different types of post-transcriptional splicing of the messenger
RNA respectively, which in turn generate two types of t-RNA
[13]. It is known that higher sRAGE levels exert a protective role,
in fact they are related to a lower risk of microvascular
complication in type 2 diabetic patients [14]. There are several
polymorphisms which could influence the transcription, the
alternative splicing of the m-RNA, thus influencing the ratio
between membrane and soluble RAGE, or the receptor affinity for
AGEs [15,16].
A relatively frequent polymorphism consisting in a substitution
of thymine with adenine (T/A) in -374 position of the gene
promoter, leading in a 3 fold increase of transcriptional activity
(17), was associated with protection toward the development of
cardiovascular disease (T/A or A/A individuals) in both diabetic
and non-diabetic individuals [17,18], although not all studies are
consistent with these findings [19,20]. Also the association between
the -374 T/A RAGE polymorphism and diabetic nephropathy is
unclear. Whereas in some studies a protective role of -374 A
genotype in diabetic nephropathy was showed [17], this finding
was not confirmed by others [21]. Indeed two studies observed the
prevalence of the A allele in patients affected by diabetic
nephropathy [22,23].
Therefore we prospectively investigated the role of this single-
nucleotide polymorphism (SNP) in the decline of renal function in
patients with mild to moderate kidney dysfunction.
Materials and Methods
Ethics Statement
This trial has been conducted according to the principles of the
Declaration of Helsinki. The trial was a substudy of CHECK
Trial. It was approved by the Ethics Committee of the University
of Study of Milan (Ethics committee UNIMI, approved on 06-02-
2001, protocol n Pr.0003). Each patient signed an informed
consent before participating to the trial.
Patients and Study Design
174 patients have been studied (119 males (68.4%): mean age
67.260.88 years; 55 females (31.6%): mean age 65.461.50 years).
All subjects were outpatients chronically followed in Nephrology
Division of Bassini Hospital (Cinisello Balsamo-Italy). Patients
affected by mild to moderate chronic kidney dysfunction (mean
GFR of 6565.65 ml/min) were enrolled. The enrolment lasted 1
month (from 1st January 2005 to 1st February 2005). Subjects were
divided into three groups, on the basis of their -374 T/A RAGE
genotype (wild type, heterozygous for the A allele, homozygous for
the A allele). Patients groups were matched for all anthropometric,
clinical and biohumoral parameters. Patients affected by any
inflammatory or infective pathologies, congenital or hereditary
kidney diseases, glomerulonephritis, malignant neoplasia, cardio-
vascular events in the 6 months before (acute myocardial
infarction, stroke, transient brain ischemic attacks, acute coronary
syndrome, carotid thromboarterectomy, percutaneous coronary
angioplasty, arterial angioplasty at the inferior limbs, coronary by-
pass, arterial by-pass at the inferior limbs), major surgery in the
previous 6 months, acute heart failure in the 6 months before,
chronic heart failure NYHA III and IV, have been excluded from
the trial. At the enrolment medical history (comprehensive of a
drug history) was investigated and examined, including arterial
pressure measurement (systolic, diastolic and mean blood pressure;
the mean values of three measurements performed every 15
minutes were registered), weight and height (for BMI calculation)
and waist circumference measurement.
Basal blood and urine samples were taken for the following
laboratory tests: urea, creatinine, electrolytes, calcium, phospho-
rus, PTH, uric acid, glycated haemoglobin, blood glucose,
haemoglobin, bicarbonates, iron assessment, albumin, lipid profile,
PCR, interleukin 6, interleukin 8, macrophage chemoattractant
protein 1, leptin, adiponectin, circulating RAGEs, albuminuria,
urinary sodium and urinary urea and a genotyping for the –374
T/A RAGE polymorphism.
GFR was assessed both as calculated creatinine clearance (using
the 24 hours urine collection) and as estimated GFR, using the
Levey’s formula [24].
Each subject was prospectively followed for 84 months and
visited every 6–9 months, even blood samples were taken for the
routine clinical biohumoral analyses (comprehensive serum
creatinine). 24 hour urine was collected and sent to our central
laboratory together with blood samples every visit.
The endpoint of the study was a rise of serum creatinine plasma
concentrations above 50% of the basal values or severe renal
dysfunction requiring dialysis treatment in the short period.
Patients who neeeded dialysis urgently went to our observation
as late referrals, having not respected the follow-up schedule.
Laboratory Methods
Blood and urine samples were collected after over-night fasted.
After centrifugation at 3.000 rpm for 12 minutes, samples were
stored at 280uC.
In sera determinations of cardiometabolic markers (total
cholesterol, HDL, triglycerides, and glycemia) as well as hepatic
enzymes (ALT, AST, cGT, CPK), creatinine and uric acid levels
were executed with colorimetric method using Cobas Mira Plus
analyzer (HoribaH, ABX, France) [25].
LDL cholesterol fraction was calculated using Friedewald
formula as described.
Fresh samples of blood were used for determination of: glycated
haemoglobin (HPLC, %), urea (enzymatic method, mg/dL),
hemoglobin (g/dL), leukocytes count (103 uL), emogas-analysis
for electrolytes detection, plasmatic albumin (electrophoresis, g/
dL), inorganic phosphorus (molybdate test, mg/dL), parathyroid
hormone (ECLIA, pg/mL), iron (ferrozine assay, ug/dL), ferritin
(ECLIA, ng/mL), transferrin and C-reactive protein (immunotur-
bidimetric, mg/dL). IL-6, IL-8 and MCP-1 levels were assessed
with BIO-PLEXTM assay (Bio-Rad, Hercules, CA, USA). Plasma
adiponectin levels (all the isoforms) were measured using a
commercial available ELISA kit (Assaypro, Winfield, MO, USA)
whereas leptin levels in plasma samples were assessed through RIA
method (Leptin Tin Human MilliporeH, St. Charles, Missouri,
USA) as described [26,27].
Genotyping
Genomic DNA was extracted using the Flexigene DNA kit
(Qiagen, Milan, Italy) [28]. Genotyping for the -374 T/A RAGE
polymorphism was performed on 1 mL (10 to 200 ng of DNA),
using a TaqMan allelic discrimination test. The primers used were
the following: FW 59- -39, REV 59- -39 and the probes were FAM-
-BQ1 and Texas Red- -BQ2.
Peripheral Blood Mononuclear Cells and Macrophages
mRNA Analysis
-374 T/A RAGE polymorphism was assessed with real time
PCR. Briefly blood diluted 1:3 in PBS (15 ml) was layered onto
4 ml of Ficoll Hipaque (Amersham) and centrifuged at 1500 rpm
-374 T/A RAGE Polymorphism in CKD
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for 35 min. Peripheral blood mononuclear cells were removed
from the interface and washed twice (10 min 1500 rpm) in PBS
before being counted. Total RNA was extracted and underwent
reverse transcription as described [29,30]. Three mL of cDNA
were amplified by real-time quantitative PCR with 1X Syber
green universal PCR mastermix (BioRad). The specificity of the
Syber green fluorescence was tested by plotting fluorescence as a
function of temperature to generate a melting curve of the
amplicon. The primers used are described elsewhere [31,32]. The
melting peaks of the amplicons were as expected (not shown). Each
sample was analyzed in duplicate using the IQ-Cycler (BioRad).
The PCR amplification was related to a standard curve ranging
from 10211 M to 10214 M.
sRAGE Levels Determination
sRAGE levels were determined via ELISA assay using
QuantikineH Human RAGE kit (R&D System, Minneapolis,
USA) as described [33]. Briefly, pre-coated microplates with
monoclonal antibody specifics for RAGE’s extracellular domain
were used. Firstly, 100 mL of Assay Diluent, 50 mL of sample
(plasma stored at 220uC) and 50 mL of RAGE standard solutions
(5000 pg/mL–2500 pg/mL–1250 pg/mL–625 pg/mL–312 pg/
mL–156 pg/mL–78 pg/mL) were added. After two hours of
incubation period at 25uC, the content of each well was aspired
and four wash cycles with Wash Buffer solution were made. Then,
the RAGE conjugate was added to react with the antibody and the
microplate was exposed to two hours of incubation at 25uC. After
another cycle of washes, Substrate Solution was added and the
colour developed proportionally to the amount of RAGE bound in
the initial step. Finally, Stop Solution (H2SO4 2 N) was added to
stop the reaction and via spectrometer lecture was made at
450 nm. Results were expressed as pg/mL.
Left Ventricular Mass was Evaluated with
Echocardiography
Echocardiograms were performed at rest with patients supine in
the left lateral side, using standard parasternal and apical views.
The overall monodimensional left ventricular measurements and
the bidimensional (apical four and two chamber) views have been
obtained according to the recommendations of the American
Society of Echocardiography. All tracings have been done and
read by a single observer blinded to the clinical characteristics of
the patients under observation. LV mass has been derived using
the formula described by Devereux and colleagues [34]:
LV Mass (grams) = 0.8061.04 [(VSTd+LVIDd+PWTd)32(L-
VIDd)3]+0.6, where VSTd is ventricular septal thickness at end
diastole, LVIDd is LV internal dimension at end diastole, and
PWTd is LV posterior wall thickness at end diastole. Left
ventricular mass has been corrected for height 2.7 (LVMI), and
expressed in units of grams/meter (g/m2.7). The presence of left
ventricular hypertrophy (LVH) has been defined for
LVMI.51 g/m2.7 in either gender.
Carotid Intima-media Thickness
Intima plus media thickness (IMT) of both carotid arteries has
been evaluated by high resolution US scan, Biosound 2000 SA
(Minneapolis, In, USA) with a 8-MHz transducer as described
[35]. Carotid artery has been scanned at the internal, at the
bifurcation and at the common carotid artery (CCA). At each
longitudinal projection the far-wall IMT, as defined by Wendelhag
[36], was measured in five standardized points, in the first
centimetre proximal to the bulb dilation. Carotid plaque has been
defined as IMT.1.3 mm. IMT has been measured on CCA
outside the plaque, if any was present. Each patient’s IMT has
been calculated taking the averages of ten measurements, 5 in the
left and 5 in the right carotid artery.
Endothelial Functionality Assessment – Flow-Mediated
Dilatation
Endothelial function was evaluated non-invasively by B-mode
ultrasonography (SA 6000C-MT, Medison, South Korea) as
described elsewhere [31]. Briefly, each subject was requested to
lie at rest for 10 min in a temperature-controlled room (21uC61),
and the first scan of brachial artery in the left arm was taken.
This was followed by inflation of a standard pneumatic
tourniquet placed around the upper arm at a pressure of
200 mmHg. After cuff removal, electrocardiography was moni-
tored continuously during the study and measurements were taken
at the end diastole.
Vessel images were taken at rest and during reactive hyperemia:
FMD was calculated 90–210 sec after the deflation of a pneumatic
tourniquet. NMD was calculated as the percentage in variation
between the basal diameter and the maximum diameter after
sublingual administration or glyceryl trinitrate 0.3 mg.
Statistical Analysis
Statistical analysis was performed using the statistical package
STATA/SE 9.2 for Windows XP. Results of the continuous
variables were expressed as Mean 6 Standard Error.
The three groups of patients (T/T, T/A and A/A -374 RAGE
genotypes) were compared each other in terms of anthropometric,
clinical, instrumental and biohumoral parameters using a one-way
ANOVA. The post Hoc analysis was performed using the
Bonferroni’s Test. The distribution of sexes, diabetes, medications,
smoke habitude among the three groups was assessed with a Chi
square. The significance was assumed for p values ,0.05.
The survival analysis was performed using the Kaplan Mayer
method. The rate of survival was compared between the three
groups of patients using the Log-Rank test. The significance was
assumed for p values ,0.05.
Finally two separate Cox multivariate models were generated
including in the analysis the -374 T/A RAGE genotype, sRAGE
and all the principal variables of nephrological interest as
covariates and the rising of serum creatinine concentrations or
dialysis as the outcome variable. The Enter method was used. The
significance was assumed for p values ,0.05.
Results
The anthropometric and biohumoral characteristics of patients
enrolled in the trial are shown in table 1. The -374 T/A RAGE
distribution was in Hardy-Weinberg equilibrium with 31.6% of
patients having the T/T genotype, 50.0% the T/A genotype and
18.4% the A/A genotype.
No significant differences among the genotypes were observed
according to age, sex, gender, mean arterial pressure, presence of
diabetes, BMI, waist circumference, smoking habits and previous
cardiovascular events (table 1).
The same was true for kidney and metabolic function; indeed
electrolytes assessments, calcium-phosphorus metabolism, glyco-
metabolic control, nutritional parameters, uric acid, hemoglobin,
iron assessment, bicarbonates serum concentrations, total choles-
terol, HDL and LDL cholesterol, triglycerides, PCR, interleukin 8,
adiponectin and leptin plasma concentrations were similar among
the genotypes (Table 1). Carries of the A allele showed significantly
higher plasma levels of interleukin 6 (T/T: 12.365.04, T/A:
30.067.89, A/A: 29.5615.83, respectively; p,0.01: T/A and A/
-374 T/A RAGE Polymorphism in CKD
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Table 1. Baseline characteristics of the population according to genotype.
RAGE T/T RAGE T/A RAGE A/A Chi square p
Sex (n6 M/F) 35/20 62/25 22/10 0.90 0.63
Diabetes (n6- %) 40 (72.7) 60 (69.0) 22 (68.8) 0.26 0.87
Smoke (n6- %) 9 (16.4) 18 (20.7) 7 (21.9) 0.53 0.76
Past cardiovascular events
(n6-%)
8 (14.5) 23 (26.4) 8 (25) 2.89 0.23
F test p
Age (years) 64,961,22 67,361,19 67.561.91 1.0 0,37
BMI (Kg/m2) 29,260,77 29,260.65 29.461.03 0.01 0.98
Waist circumference (cm) 103.561,96 102.661,63 105.162.63 0.87 0.41
Mean arterial pressure (mmHg) 107.562.57 102.161.30 101.161.89 2.98 0.054
PTH (pg/mL) 98.7621.27 72.5611.13 77.3611.68 0.85 0,42
Hemoglobin (g/dL) 13.360.23 13.160.22 13.360.30 0.23 0.79
Glycated Hemoglobin (%) 6.760.20 6.960.77 6.960.21 0.75 0.47
Uric acid (mg/dL) 6.160.20 6.760.54 6.460.27 0.34 0.71
Urea (mg/dL) 57.264.47 66.164.84 58.865.86 0.95 0.38
Creatinine (mg/dL) 1.4860.14 1.660.12 1.460.12 0.47 0.62
eGFR (mL/min) 67.765.43 57.263.62 65.067.30 1.41 0.24
Calculated GFR (mL/min) 70.369.42 59.264.91 58.1612.29 0.73 0.48
Na (mmol/L) 134.660.76 133.960.06 134.460.09 0.29 0.74
K (mmol/L) 4.360.10 4.360.07 4.260.11 0.56 0.56
Ca x P product (mg/dL) 29.561.30 30.361.18 28.161.69 0.57 0.56
Serum Bicarbonates (mmol/L) 26.660.61 25.960.36 27.360.61 1.77 0.17
Serum Iron (mg/dL) 55.765.62 59.763.59 47.967.13 1.26 0.28
Transerrin (mg/dL) 244610.02 255.666.26 264.2614.2 0.89 0.41
Ferritin (ng/mL) 175626.06 161.3621.61 116.6620.65 1.03 0.36
Albumin (g/dL) 4.360.04 4.260.04 4.260.10 1.49 0.22
Total cholesterol (mg/dL) 19.966.25 203.765.22 207.867.36 0.59 0.55
HDL cholesterol (mg/dL) 5262.40 48.461.37 50.862.57 1.04 0.35
LDL cholesterol (mg/dL) 117.265.59 122.964.67 126.467.32 0.53 0.58
Triglycerides (mg/dL) 40.564.26 38.163.33 38.065.59 0.11 0.89
24 h urinary sodium (mmol/24 h) 164.7611.63 162.668.10 182.2619.25 0.63 0.53
24 h urinary urea (g/24 h) 2.060.98 2.161.02 2.460.37 1.01 0.36
CRP (mg/dL) 0.3360.067 0.3060.055 0.4460.165 0.59 0.55
Albuminuria (mg urinary albumin/
mmol urinary creatinine
43.7613.83 73.1616.37 24.369.78 2.22 0.11
LVM (g/h2.7 ) 50.662.45 53.261.89 57.263.78 1.29 0.27
Carotid Intima-Media Thickness
(mm)
0.7860.029 0.7960.025 0.7660.031 0.12 0.88
Flow mediated brachial artery
dilation (%)
13.661.08 11.260.84 15.363.07 2.11 0.12
Adiponectin (mg/mL) 18.261.46 19.561.32 18.262.17 0.27 0.76
Leptin (ng/mL) 19.963.82 20.062.18 19.064.14 0.02 0.97
Serum RAGE (pg/mL) 1633.86137.22 1950.76108.7 1626.86121.1 2.42 0.09
Interleukin 6 (pg/mL) 12.365.04 30.067.89 29.5615.83 1.13 0.01
Interleukin 8 (mg/dL) 70.1624.98 47.5610.44 56.1619.77 0.46 0.63
Macrophages chemoactrant
protein 1 (pg/mL)
293.5636.20 411.8648.41 347.1639.87 1.63 0.04
The anthropometric parameters, the prevalence of past cardiovascular events (myocardial infarction, acute coronary syndrome, stroke, transient ischemic attacs, by-
passes at the inferior limbs, angioplasty, aorto-coronary by-passes) and biohumoral parameters are compared between patients carrying the –374 T/T,T/A and A/A
genotypes of RAGE. Significance have been taken for p values ,0.05, using a single way ANOVA: the post-hoc analysis showed a statistically significant difference
between T/T and T/A subjects vs A/A subjects in terms of Interleukin 6 and Macrophages chemoattractant protein 1. No differences have been seen in terms of renal
function, albuminuria, intermediate cardiovascular organ damage, inflammatory parameters or nutritional parameters between the three groups of subjects.
doi:10.1371/journal.pone.0060089.t001
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A vs T/T ) and macrophages chemoattractant protein 1 (T/T:
293.5636.20, T/A: 411.8648.41, A/A: 347.1639.87, respective-
ly; p = 0.04: T/A and A/A vs T/T) compared to T/T subjects
while plasma levels of sRAGE were only slightly increased (T/T:
1633.86137.22 pg/mL, T/A: 1950.76108.7 and A/A:
1626.86121.1 pg/mL, p= 0,09).
The presence of the -374 T/A SNP was not associated with
subclinical cardiovascular disease, in fact carotid intima-media
thickness, flow mediated brachial artery vasodilation and left
ventricular mass were not statistically different among the RAGE
genotypes. Finally the distribution of anti-hypertensive, anti-
diabetic or lipid-lowering therapies was similar among the three
groups (table 2).
During the follow-up period we observed 40 events compre-
hensive of the serum creatinine increase of more than 50% of the
basal values and need of dialysis (22%).
Survival analysis showed a faster decline of renal function in
carriers of the A allele compared to TT subjects (Log-Rank test:
Chi square = 6.34, p= 0,018) (fig. 1).
Differences in renal survival were also maintained when the
three genotypes were analyzed independently; with a significant
difference in terms of survival between T/T subjects and T/A and
A/A subjects (Log-Rank test: Chi square = 6.84, p = 0,03) (fig. 2).
Overall T/T subjects presented a mean percentage of endpoint
achievement of 8960.04% at 67 months, those belonging to T/A
group showed a mean percentage of endpoint achievement
7060.04% at 75 months and patients carrying the A/A genotype
7560.07% at 74 months.
Furthermore multivariate analysis was then performed to
identify among albuminuria, LDL-cholesterol, HDL-cholesterol,
-374 T/A RAGE, BMI, GFR, mean arterial pressure, haemoglo-
bin levels and calcium-phosphorus product, the main predictors of
renal function decline (Table 3). As expected, albuminuria resulted
the main predictor [Wald test 6.550 and a mean Hazard ratio of
1.015 (increased risk of reaching the end point of 1.5% for each
mg/l in more of albuminuria) (IC 95%: 1.003–1.025), p = 0.01]
followed by the-374 RAGE polymorphism [Wald test of 4.330 and
a mean Hazard ratio of 2.724 (increased risk of reaching the end
point of 2.724 fold higher for subjects carrying the A allele than
those carrying T/T genotype) (IC 95%: 1.060–6.998), p = 0.037],
LDL cholesterol [Wald test of 4.310 and an Hazard ratio of 1.009
(increased risk of reaching the end point of 0.9% per each mg/dl
increase of LDL cholesterol) (IC 95%:.1.000–1.017, p= 0.038)],
HDL cholesterol [Wald test of 5.253 and an Hazard Ratio of
0.958 (decreased risk of reaching the end point of 5% per each
mg/dl in more of HDL cholesterol) (IC 95%: 0.941–0.995,
p = 0.022)] and BMI [Wald test of 4.215 and an Hazard ratio of
0.933 (decreased risk of reaching the end point of 0.7% per each
Kg/m2 in more of BMI) (IC 95%: 0.873–0.997, p= 0.040)].
In the second multivariate model including albuminuria, LDL-
cholesterol, HDL-cholesterol, sRAGE, BMI, GFR, mean arterial
pressure, haemoglobin levels and calcium-phosphorus product,
only albuminura [Wald test 6.5 and a mean Hazard ratio of 1.016
(increased risk of reaching the end point of 1.6% for each mg/l in
more of albuminuria) (IC 95%: 1.004–1.029), p = 0.01] followed
by HDL cholesterol [Wald test of 5.26 and a mean Hazard ratio of
0.97 (reduced risk of reaching the end point of 3% per each mg/dl
in more of HDL cholesterol) (IC 95%: 0.94–0.99), p = 0.031]
predictors of CKD progression (Table 4).
Discussion
Our results show that CKD patients with the –374 RAGE A
allele have a poor CKD prognosis compared to carriers of the TT
genotype. Although the role of –374 T/A RAGE in CKD
progression has not been extensively investigated, some cross-
sectional studies showed an association of the A allele with CKD in
diabetic subjects [22,23], in contrast with the protective role
exerted by this allele toward cardiovascular disease [21]. To the
best of our knowledge, our trial is the first which prospectively
shows a direct relationship between –374 T/A RAGE polymor-
phism and the decline of kidney function in patients with
cardiovascular renal disease. Of note, a recent meta-analysis
showed that other SNPs known to affect RAGE transcription are
not associated with the prevalence of diabetic nephropathy [37]
further supporting the relevance of our finding.
This finding suggests that the presence of the T allele is
protective toward the decline of kidney function compared to a
Table 2. Prevalence of medications according to genotypes.
Medication yes/no (n6- % of all
patients studied) RAGE T/T (n6=55) RAGE T/A (n6=87) RAGE A/A (n6=32) Chi square p
ASA/Ticlopidine 22/33(40.0) 37/50 (42.5) 18/14(56.3) 2.37 0.30
Allopurinol 12/43(21.8) 14/73(16.1) 4/28(12.5) 1.39 0.49
Statins or fibrates 20/35(36.4) 28/59 (32.2) 16/16(50.0) 3.2 0.20
b blockers or ab Blockers 10/45(18.2) 20/67 (23.0) 6/26(18.8) 0.56 0.75
Clonidine 0/55 (0) 3/84 (3.4) 1/31(3.1) 1.90 0.38
a antagonists 2/53 (3.6) 11/76(12.6) 2/30(6.3) 3.75 0.15
Calcium channel blockers (DDP and
NDDP)
10/45(18.2) 26/61(29.9) 10/22(31.3) 2.84 0.24
Diuretics 18/37(32.7) 32/55 (36.8) 13/19 (40.6) 0.57 0.75
ARBs 21/34(38.2) 26/61 (29.9) 10/22 (31.3) 1.09 0.57
ACE inhibitors 28/27(50.9) 36/51 (41.4) 17/15 (53.1) 1.91 0.38
Oral antidiabetics 27/28 (49) 33/54 (37.9) 15/17 (46.9) 1.93 0.37
Insulin 7/48 (12.7) 19/68 (21.8) 2/30(6.3) 4.88 0.09
Medications: no differences have been found between patients carrying –374 T/T, T/A and A/A genotypes in terms of antihypertensive or antidiabetic therapy. A
Pearson Chi square test was used, keeping a significant difference for p values ,0.05.
doi:10.1371/journal.pone.0060089.t002
-374 T/A RAGE Polymorphism in CKD
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e60089
potential protective effect of the A allele in cardiovascular
disorders showed in previous studies [21]. The molecular
mechanisms behind this effect need further investigations. The
presence of the -374 A allele is associated with increased RAGE
transcription [16]; however, while the increase in RAGE plasma
levels observed in carriers of the A allele was not statistically
significant we cannot exclude that specific isoforms of RAGE are
differently affected. Indeed, the transcription of the RAGE
towards the soluble form rather than the membrane form depends
on a different post-transcriptional splicing of the messenger RNA
(38). It is known that higher sRAGE levels exert a protective role,
in fact they are related to a lower risk of microvascular
complication in type 2 diabetic patients [14]. However sRAGE
levels are contributed both by the original spliced isoforms but also
by the cleaved membrane receptor [38], with potentially different
roles. Of note, in vitro experiments have shown that AGEs-RAGE
Figure 1. Renal survival of patients carrying –374 T/T and the A allele. The figure shows that the subjects carrying the A allele present a
faster decline of renal function than wild type patients. The main endpoint of the analysis was an increase of serum creatinine over 50% or the
beginning of chronic dialysis. The figure shows a total of 40 events: 6 in T/T subjects, 34 in subjects carrying the A allele.
doi:10.1371/journal.pone.0060089.g001
Figure 2. Renal survival of wild-type, heterozygous and homozygous patients for the A allele. The figure shows that T/A and A/A
subjects present a faster decline of renal function than T/T patients. The main end point of the analysis was an increase of serum creatinine over 50%
or the beginning of chronic dialysis. Figure shows a total of 40 events: 6 in T/T subjects, 26 in T/A subjects and 8 in A/A subjects.
doi:10.1371/journal.pone.0060089.g002
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interaction is involved in the progression of renal damage by
inducing mesangial fibrosis, glomerular sclerosis and the expres-
sion of vascular endothelial grow factor (VEGF) and MCP1 by
mesangial cells [39,40], which in turn could support monocyte
mesangial infiltration in early phase of diabetic nephropathy [41].
AGEs-RAGE interaction stimulates mesangial cells production of
insulin grow factor-1 and 2, platelet derived grow factor (PDGF)
and transforming grow factor–b (TGF-b), which further promote
mesangial production of type IV collagen, laminin and fibronectin
[39–41]. Moreover AGEs-RAGE interaction also increases TGF-
b expression by podocytes and proximal tubular cells, leading to
glomerulosclerosis and tubule-interstitial fibrosis [42]. Further-
more in vivo experiments in rats showed that infusion of AGE-
albumin induced glomerular hypertrophy, overexpression of type
IV collagen, laminin B1 and TGF-b [42,43,44]. AGEs-RAGE
interaction and also other metabolic factors such as HDL also
increases TGF-b expression by podocytes and proximal tubular
cells, leading to glomerulosclerosis and tubule-interstitial fibrosis
[45,46]. All these aspects clearly point to an involvement of the
AGEs-RAGE in CKD progression. AGEs promote inflammation
[47] by binding RAGE on the surface of macrophages,
lymphocytes, endothelial cells and mesangial cells; the observation
that in our cohort carriers of the A allele present increased levels of
MCP-1 and IL-6 could support the concept of an higher
inflammatory mediated kidney function decline in A carriers.
Cox analysis showed that also albuminuria and LDL cholesterol
were independent predictors of CKD progression in agreement
with the CKD protective effects of therapies aimed at improving
proteinuria such as RAS inhibitors or lipid profile [48] such as
HMGCoA reductase inhibitors [49].
The Cox analysis also showed an inverse relationship between
BMI and CKD progression. Although this finding could seem
somehow confounding, given that BMI, an obesity marker as waist
circumference, is a risk factor for the development and the
progression of chronic renal dysfunction [50], our data support the
hypothesis that BMI could inversely reflect patient’s lean mass and
malnutrition, which is highly prevalent among CKD patients at
risk of progression [51].
We have to acknowledge some limitations of our study: firstly,
we enrolled patients who already presented some degree of renal
dysfunction which could result in minor differences among the
genotypes. However, the long follow-up (84 months) allowed to
appreciate prospectively the association of the A allele to kidney
function decline compared to that of TT.
Table 3. Cox regression for the decline of renal function including -374 T/A RAGE.
Covariates Beta
Beta Standard
Error wald p Hazard Ratio CI Hazard ratio
Haemoglobin (g/dL) 20.156 0.114 1.854 0.172 0.855 0.584–1.070
GFR (mL/min) 20.005 0.007 0.477 0.490 0.995 0.982–1.009
Albuminuria (mg/L) 0.015 0.006 6.550 0.01 1.015 1.003–1.025
Mean arterial pressure (mmHg) 0.21 0.015 2.011 0.153 1.021 0.992–1.051
-374 A RAGE 1.002 0.481 4.330 0.037 2.724 1.060–6.998
Ca x P product (mg/dL) 0.059 0.032 3.285 0.070 1.060 0.995–1.130
HDL Cholesterol (mg/dL) 20.033 0.014 5.253 0.022 0.958 0.941–0.995
LDL Cholesterol (mg/dL) 0.008 0.004 4.310 0.038 1.009 1.000–1.017
BMI (Kg/m2) 20.059 0.034 4.215 0.040 0.933 0.873–0.997
Cox regression. Table shows that –374 A RAGE genotype, together with albuminuria, LDL cholesterol, HDL cholesterol and BMI are significantly associated with the
decline of renal function. –374 A allele for RAGE, albuminuria and LDL cholesterol are predictor of CKD progression, while HDL cholesterol and BMI are inversely
associated with renal function decline.
doi:10.1371/journal.pone.0060089.t003
Table 4. Cox regression for the decline of renal function including the levels of the soluble form of RAGE.
Covariates Beta
Beta Standard
Error wald p Hazard Ratio CI Hazard ratio
Hemoglobin (g/dL) 20.145 0.112 1.850 0.176 0.841 0.656–1.080
GFR (mL/min) 20.001 0.004 0.423 0.948 1.004 0.987–1.013
Albuminuria (mg/L) 0.013 0.005 6.500 0.010 1.016 1.004–1.029
Mean arterial pressure (mmHg) 0.20 0.012 2.014 0.080 1.019 0.998–1.042
Tertiles sRAGE (pg/mL) 20.003 0.005 0.530 0.590 1.001 0.991–1.005
Ca x P product (mg/dL) 0.061 0.038 3.310 0.185 1.045 0.978–1.116
HDL Cholesterol (mg/dL) 20.034 0.014 5.260 0.031 0.969 0.942–0.997
LDL Cholesterol (mg/dL) 0.075 0.048 2.102 0.105 1.007 0.998–1.016
BMI (Kg/m2) 20.118 0.015 2.015 0.099 0.938 0.861–1.012
Cox regression. Table 3b shows that replacing sRAGE rather than –374 A RAGE genotype in the same model showed in table 3a, only albuminuria, and HDL cholesterol
are significantly associated with the decline of renal function.
doi:10.1371/journal.pone.0060089.t004
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Secondly, we investigated a relatively limited number of CKD
patients, however the frequencies of the -374T/A genotypes are
similar to those reported in larger cohorts [18,20], thus suggesting
that our findings could set the stage for further confirmation in
larger CKD cohorts. We cannot exclude that studying prospec-
tively a cohort of subjects, all with a normal renal function and a
longer follow-up could result in additional predictors.
In conclusion, our data support the role of AGEs-RAGE system
in the progression of chronic renal dysfunction and suggest a
potential target to further improve the management of CKD
progression toward dialysis given that the conventional strategies
are not sufficiently effective. Future studies addressing markers of
inflammation and of angiogenesis are needed to clarify the
pathophysiological mechanisms of AGEs-RAGE system activation
and the association between the chronic inflammatory status and
the consecutive kidney remodelling in relation to the RAGE status.
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